Journal Article

Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial

Kruger, Dawie, Gropper, Savion, Vahed, Yacoob, Albareda, Nuria, Gani, Mashra, Chelius, Klaus, Mitha, Ismail, García-Alonso, Fernando

2014

Overview

We compared the efficacy and safety of ozenoxacin (a new nonfluorinated quinolone) 1% cream with placebo in the treatment of impetigo. In a randomized, double-blind, multicenter study, patients received ozenoxacin cream or placebo cream twice daily for 5 days (a third group received retapamulin 1% ointment as a control). Clinical, microbiological and laboratory evaluations were performed during follow-up (over 2 weeks). Ozenoxacin was superior to placebo (success rate 34.8 vs 19.2%; p = 0.003). Microbiological success was 70.8% for ozenoxacin and 38.2% for placebo after 3-4 days and 79.2% versus 56.6% after 6-7 days. Ozenoxacin produced more rapid microbiological clearance than retapamulin. All treatments were well tolerated. Ozenoxacin 1% cream was effective and safe in the treatment of impetigo.

• Publisher: Future Medicine Ltd
• Subject: Adolescent / Aminopyridines - therapeutic use / Anti-Bacterial Agents - therapeutic use / Antibiotics / Bacterial infections / Bridged Bicyclo Compounds, Heterocyclic - therapeutic use / Child / Child, Preschool / Clinical medicine / Clinical trials / Comparative analysis / Dose-Response Relationship, Drug / Double-Blind Method / Drug therapy / Female / Follow-Up Studies / Humans / Impetigo / Impetigo - drug therapy / Male / Ointments / ozenoxacin / Patient outcomes / Quinolones - therapeutic use / retapamulin / Skin / skin infection / Staphylococcus infections / Success / Topical drugs